NCT01716806 2024-06-11A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)Seagen Inc.Phase 2 Completed131 enrolled 28 charts
NCT03927105 2024-03-18Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell LymphomaUniversity of Michigan Rogel Cancer CenterPhase 2 Completed4 enrolled 11 charts